Stroke Trial, Recruiting NCT06092554 Sponsor: University of Bari Condition: Stroke
Back to Stroke

Stroke Trial, Recruiting

NCT06092554
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 80 years of age.
  • People who have recently experienced a head injury that also involved at least one other part of the body being injured, OR people who have had a stroke or bleeding in the brain with no signs of lung infection caused by inhaling fluid or food.
  • People who have been placed on a breathing machine (mechanical ventilator) — for brain trauma cases, this must have started in the ambulance or emergency department; for stroke or brain bleed cases, it must have started immediately after the event.
  • People whose doctors expect them to need the breathing machine for at least six days.
  • People for whom written consent has been given — either by the patient themselves or by their legal representative.

Who may not be able to join:

  • People who have already been on a breathing machine for more than 72 hours before screening for the trial begins.
  • People who are pregnant or breastfeeding.
  • People with a weakened immune system, as there may be a risk of infection from the probiotic used in the trial. This includes people with HIV with a very low immune cell count (below 200 CD4 cells/μL), people taking long-term immune-suppressing medications (such as azathioprine, cyclosporine, cyclophosphamide, tacrolimus, methotrexate, mycophenolate, or Anti-IL2), people who have had an organ or tissue transplant at any point in their life, people who have needed chemotherapy for cancer within the last 3 months, and people with very low levels of infection-fighting white blood cells (neutrophil count below 500).
  • People whose main diagnosis is severe inflammation of the pancreas (a Ranson score of 3 or higher) — note that mild or moderate pancreatitis does not exclude someone from joining.
  • People with reduced blood flow to the bowel (ischemic bowel disease).
  • People with injuries or sores in the mouth or throat area.
  • People who are unable to receive medications through a feeding tube or by mouth.
  • People whose ICU doctor has decided that advanced life support will be withdrawn.
  • People who have certain heart or blood vessel conditions that may increase the risk of infection spreading through the bloodstream. This includes people with rheumatic heart disease, congenital (present from birth) valve disease, certain repaired or unrepaired heart defects, artificial or biological heart valves, a history of infection of the heart's inner lining (endocarditis), certain permanent devices in their blood vessels (such as large artery stents, grafts for aortic aneurysm repair, vena cava filters, or dialysis grafts), long-term dialysis catheters tunnelled under the skin, or a pacemaker or defibrillator. (Note: certain other devices such as short-term catheters, coronary stents, bypass grafts, or neurovascular coils do not exclude someone — confirm with trial site if unsure.)
  • People who have sepsis (a serious, body-wide response to infection) or septic shock.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Filomena Puntillo, MD, PhD, University of Bari

Phone: +393280072443

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Bari
Registry
ClinicalTrials.gov
Start date
13 December 2023
Est. completion
15 July 2026

Where this trial is recruiting

🇧🇪 Belgium 🇮🇹 Italy

Primary endpoints

Vap Incidence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov